PGILX
Price
$39.16
Change
+$0.42 (+1.08%)
Updated
Sep 4 closing price
Net Assets
705.97M
RGEBX
Price
$82.44
Change
+$0.19 (+0.23%)
Updated
Sep 5 closing price
Net Assets
331.65B
Interact to see
Advertisement

PGILX vs RGEBX

Header iconPGILX vs RGEBX Comparison
Open Charts PGILX vs RGEBXBanner chart's image
Putnam Focused Equity Y
Price$39.16
Change+$0.42 (+1.08%)
VolumeN/A
Net Assets705.97M
American Funds Growth Fund of Amer R2E
Price$82.44
Change+$0.19 (+0.23%)
VolumeN/A
Net Assets331.65B
PGILX vs RGEBX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
PGILX vs. RGEBX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PGILX is a Buy and RGEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGEBX has more cash in the bank: 332B vs. PGILX (706M). PGILX pays higher dividends than RGEBX: PGILX (0.29) vs RGEBX (0.00). PGILX was incepted earlier than RGEBX: PGILX (17 years) vs RGEBX (11 years). RGEBX (1.09) is less costly to investors than PGILX (0.86). PGILX is a more actively managed with annual turnover of: 30.00 vs. RGEBX (25.00). PGILX has a lower initial minimum investment than RGEBX: PGILX (0) vs RGEBX (250). RGEBX annual gain was more profitable for investors over the last year : 17.32 vs. PGILX (11.47). PGILX return over 5 years is better than : 66.90 vs. RGEBX (38.39).
PGILXRGEBXPGILX / RGEBX
Total Expense Ratio0.861.0979%
Annual Report Gross Expense Ratio0.861.0979%
Fund Existence17 years11 years-
Gain YTD12.30315.13281%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets706M332B0%
Annual Yield % from dividends0.290.00-
Returns for 1 year11.4717.3266%
Returns for 3 years53.3457.2493%
Returns for 5 years66.9038.39174%
Returns for 10 years154.4991.00170%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARTV3.610.50
+16.08%
Artiva Biotherapeutics Inc
ARCT17.851.09
+6.50%
Arcturus Therapeutics Holdings
MANH215.315.45
+2.60%
Manhattan Associates
TRMD23.020.25
+1.10%
TORM plc
INDP3.30-1.31
-28.35%
Indaptus Therapeutics Inc